Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Feb;45(1):92-7.
doi: 10.1007/s12020-013-9928-8. Epub 2013 Mar 23.

Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile

Affiliations
Comparative Study

Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile

Mario Rotondi et al. Endocrine. 2014 Feb.

Abstract

Morbid obesity is associated with a high rate of raised serum TSH associated with normal free thyroid hormones. The body repercussions of this thyroid abnormality, suggesting subclinical hypothyroidism, are still debated. In particular, it is unclear whether the raised serum TSH of obesity results in changes of circulating lipids typically observed in hypothyroidism. Aim of this study was to evaluate the impact of a raised serum TSH on the lipid profile in morbid-obese and non-obese patients. Serum TSH, FT4, FT3, Tg-Ab, TPO-Ab and lipids were measured in 55 morbid-obese (BMI > 40 kg/m(2)) and 55 non-obese (BMI < 30 kg/m(2)) patients with a raised serum TSH. Despite similar serum levels of TSH, FT4 and FT3, morbid-obese patients displayed significantly lower mean levels of total cholesterol (200.8 ± 35.6 vs. 226.9 ± 41.4 mg/dl, p < 0.001) and a significantly lower prevalence of hypercholesterolemia (50.9 vs. 72.7 %, p < 0.01) when compared with non-obese patients. Morbid-obese patients also had lower mean serum HDL cholesterol and higher serum triglycerides. The impact of a raised serum TSH on the lipid profile differs in morbid-obese compared to non-obese patients, suggesting that obese patients might not be truly hypothyroid. Measuring total cholesterol could be a helpful tool for deciding whether a morbid-obese patient with a raised serum TSH should be given levothyroxine treatment.

PubMed Disclaimer

References

    1. Clin Endocrinol (Oxf). 2006 Feb;64(2):125-8 - PubMed
    1. J Clin Endocrinol Metab. 2005 Jul;90(7):4019-24 - PubMed
    1. Thyroid. 2006 Jan;16(1):73-8 - PubMed
    1. Clin Endocrinol (Oxf). 2005 Apr;62(4):487-91 - PubMed
    1. J Clin Endocrinol Metab. 2008 Jun;93(6):2027-34 - PubMed

Publication types

MeSH terms

LinkOut - more resources